TCL Archive FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly. May 6, 2005
TCL Archive Oxaliplatin Regimens Extend Survival Of Advanced Colorectal Cancer, Study Finds June 27, 2003
TCL Archive NTP Committee Finds Five Test Reports Show “Limited” Evidence Of Carcinogenicity February 27, 1981
TCL Archive J&J To Eliminate Its Ortho Biotech Unit As FDA Considers Further Limits On ESAs. May 2, 2008